Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non–Small-Cell Lung Cancer in the United States and Vietnam
暂无分享,去创建一个
H. Stehr | J. Neal | H. Wakelee | M. Diehn | Richard A. Thorp | Anh-Hoa Nguyen | Li Zhou | P. N. Hiệp | K. Nguyen | Nguyen Van Cau | Phan Canh Duy | P. Duy
[1] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[2] H. A. Vu,et al. Spectrum of EGFR gene mutations in Vietnamese patients with non–small cell lung cancer , 2016, Asia-Pacific journal of clinical oncology.
[3] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[4] Jeffrey W. Clark,et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[5] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[6] S. Thongprasert,et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[8] S. Ou,et al. Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] T. Gu,et al. Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion , 2012, Clinical Cancer Research.
[10] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[11] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[12] Masahiro Fukuoka,et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Ladanyi,et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] David N Louis,et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.
[15] S. Ou,et al. A Comparison Study of Clinicopathologic Characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) Patients by Smoking Status , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[17] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[18] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Ping Yang,et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. , 2009, Human pathology.
[20] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[21] Y. Ishikawa,et al. Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.
[22] Derek Y. Chiang,et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.
[23] Francesca Demichelis,et al. EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.
[24] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[26] Moon S. Chen,et al. Cancer Incidence, Mortality, and Associated Risk Factors Among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese Ethnicities , 2007, CA: a cancer journal for clinicians.
[27] D. West,et al. Cancer incidence patterns among Vietnamese in the United States and Ha Noi, Vietnam , 2002 .